SBRT Combined with Pabolizumab in Advanced Non-Small Cell Lung Cancer
Objective To investigate the effect of stereotactic body radiotherapy(SBRT)com-bined with pabolizumab on the survival and tumor response in patients with advanced non-small cell lung cancer(NSCLC).Methods The medical records of NSCLC patients who received paboli-zumab chemotherapy at our hospital from 2019 to 2020 were retrospectively analyzed,and a total of 116 patients who met the criteria were included;a total of 32.8％(38/116)of the patients re-ceived SBRT and were established as the combination group,and the remaining patients were cat-egorized as the monotherapy group.The median progression-free survival(PFS)and overall sur-vival(OS)of the 2 groups were assessed using the Kaplan-Meier model.The occurrence of adverse reactions in the 2 groups was recorded and compared.Results The median PFS for the entire co-hort was 12.00 months(95％CI:10.17 to 13.83),and the median OS was 23.43 months(95％CI:20.04 to 26.82).Multivariate analysis showed that SBRT was an independent predictor of PFS(HR:0.45,95％CI:0.65-0.93,P=0.020)and OS(HR:0.32,95％CI:0.53-0.87,P=0.013).The median PFS was 13.97 months(95％CI:12.04-15.89)in the combination group compared with 10.08 months(95％CI:7.90-12.27)in the monotherapy group(P=0.016);the median OS was 30.67 months(95％CI:22.20-39.14)in the combination group compared with 21.97 months(95％CI:18.64-25.30)in the monotherapy group(P=0.011).The difference in overall adverse event rates in the 2 groups was not statistically significant(P＞0.05);the incidence of grade 3 or higher pneumonia was slightly higher in the combination group than in the monotherapy group(7.89％vs.3.87％),but the difference was not statistically significant(P=0.350).Conclusion SBRT com-bined with pabolizumab could improve PFS and OS in patients with advanced NSCLC without in-creasing treatment toxicity.
stereotactic body radiotherapypabolizumabadvanced non-small cell lung cancertumor response
NETL
NSTL
万方数据
